There were 583 press releases posted in the last 24 hours and 149,561 in the last 365 days.

Global Rectal Cancer Drugs and Companies Pipeline Review H1 2016

Rectal Cancer Treatment Pipeline Review H1 2016

PUNE, INDIA, September 19, 2016 / -- Rectal Cancer - Pipeline Review, H2 2016
‘Rectal Cancer - Pipeline Review, H2 2016’, provides an overview of the Rectal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Complete report details @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @

- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rectal Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key Points in Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rectal Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Rectal Cancer - Overview 7
Rectal Cancer - Therapeutics under Development by Companies 8
Rectal Cancer - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Rectal Cancer - Products under Development by Companies 11
Rectal Cancer - Companies Involved in Therapeutics Development 12
AbbVie Inc 12
Advaxis, Inc. 13
Cerulean Pharma, Inc. 14
Hanwha Chemical Corporation 15
Karyopharm Therapeutics, Inc. 16
Regeneron Pharmaceuticals Inc 17
Taiwan Liposome Company, Ltd. 18
Rectal Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
axalimogene filolisbac - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CRLX-101 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ganetespib - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
HD-204 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
nimotuzumab - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
selinexor - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
TLC-388 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
veliparib - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
ziv-aflibercept - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Rectal Cancer - Dormant Projects 104
Rectal Cancer - Product Development Milestones 105
Featured News & Press Releases 105
Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting 105
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

Buy this report @

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here